The registry shows the Phase 2 obesity trial of eloralintide reached primary completion
Phase IIP1Primary public evidenceTrial registry record
ClinicalTrials.gov lists 30 May 2025 as the primary completion date of NCT06230523, the Phase 2 placebo-controlled trial of eloralintide in 263 adults with obesity or overweight. The record gives 14 August 2025 as the study completion date and has a results section.
263
Participants, as recorded in the registry
48 weeks
Primary endpoint time point: percent change in body weight
Background and context
Where this trial sits
The record lists this study as one that ran under the chronic weight management master protocol (NCT06143956). It compares eloralintide with placebo, double-blind, and the primary endpoint is percent change in body weight from baseline to week 48. Participation lasted about 64 weeks.
Who took part
Adults aged 18 to 75 met the master protocol criteria, a BMI of at least 30 or at least 27 with a weight-related condition. People with diabetes, a history of pancreatitis, a history of bradyarrhythmia or sinus bradycardia, or a recent heart attack, stroke, unstable angina or heart failure hospitalisation were excluded. All listed sites are in the United States.
Where the results are
The record has a results section on the registry, which this entry does not restate. The peer-reviewed paper and the sponsor announcement have their own entries in this section. The study completed on 14 August 2025.
Trial record: ClinicalTrials.gov NCT06230523, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
